Vertex Pharmaceuticals
VRTX
$546.12
-2.12%
Vertex Pharmaceuticals is a global biotechnology company focused on discovering and developing small-molecule drugs for serious diseases, with a core franchise in cystic fibrosis (CF) therapies including Kalydeco, Orkambi, Symdeko, Trikafta/Kaftrio, and Alyftrek. As the undisputed leader in CF treatment, Vertex has established a near-monopoly in this niche, and is now diversifying into gene editing (Casgevy), pain management (Journavx), and kidney disease. The current investor narrative centers on the company's successful expansion beyond CF, highlighted by the $10 billion acquisition of Crinetics Pharmaceuticals, positive Phase 3 data for its kidney drug, and the potential of its type 1 diabetes cell therapy, which are driving renewed growth optimism and a recent stock rally.…
VRTX
Vertex Pharmaceuticals
$546.12
Related headlines
Investment Opinion: Should I buy VRTX Today?
Rating: Buy. Vertex is a high-quality biotech with a dominant CF franchise and a promising pipeline, but the current valuation leaves limited upside to analyst targets. The consensus 'Buy' rating and average target of $563.12 support a positive outlook, though the modest upside suggests a hold for near-term investors.
Sign up to view all
VRTX 12-Month Price Forecast
Vertex's fundamentals are solid, with a dominant CF franchise and a pipeline that could re-accelerate growth. The valuation is reasonable for a company with its growth prospects, but the limited upside to analyst targets suggests the market is already pricing in success. I am cautiously bullish, as the pipeline catalysts (kidney drug, Casgevy) could drive upside, but execution risks and a high premium for Crinetics warrant a medium confidence. I would upgrade to high confidence if the kidney drug is approved and initial sales exceed expectations, and downgrade to neutral if pipeline setbacks occur.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Vertex Pharmaceuticals's 12-month outlook, with a consensus price target around $569.54 and implied upside of +4.3% versus the current price.
Average Target
$569.54
0 analysts
Implied Upside
+4.3%
vs. current price
Analyst Count
—
covering this stock
Price Range
$350 - $672
Analyst target range
Vertex is covered by 25 analysts, with a consensus recommendation of 'Buy' (mean rating of 1.66 on a 1-5 scale). The average price target is $563.12, implying a modest upside of 3.96% from the current price of $541.69. The target range is wide, from a low of $350 to a high of $672, reflecting significant uncertainty about the company's pipeline and market expansion. The high target assumes successful commercialization of new drugs like Casgevy and the kidney therapy, while the low target likely prices in competitive threats or pipeline failures. Recent ratings have been mostly positive, with reaffirmations of Buy/Outperform from Truist, UBS, RBC, and Morgan Stanley, though Baird maintains an Underperform, indicating some bearish sentiment.
Bulls vs Bears: VRTX Investment Factors
Vertex presents a compelling bull case with its dominant CF franchise, strong profitability, and promising diversification into gene editing, pain, and kidney disease. The bear case centers on decelerating growth, high valuation with limited analyst upside, and execution risks in new launches and acquisitions. Currently, the bull case has stronger evidence, given the company's robust financials and pipeline progress, but the key tension is whether new products can re-accelerate growth to justify the premium valuation. If pipeline milestones succeed, the stock could re-rate higher; if they disappoint, the downside could be significant.
Bullish
- Dominant CF franchise with near-monopoly: Vertex holds a near-monopoly in cystic fibrosis (CF) therapies, with Trikafta/Kaftrio generating $2.35 billion in Q1 2026 alone. The recent failure of a rival's CF drug reinforces its market leadership, ensuring sustained revenue and pricing power.
- Diversification into high-growth areas: Vertex is expanding beyond CF with Casgevy (gene editing), Journavx (pain), and a promising kidney drug. The $10 billion Crinetics acquisition adds a commercialized drug and pipeline, potentially generating $5 billion in annual sales, while positive Phase 3 kidney data positions it for FDA approval by year-end.
- Strong profitability and cash flow: Vertex boasts a gross margin of 85% and an operating margin of 39.4%, with Q1 2026 net income of $1.03 billion. Free cash flow over the trailing twelve months is $3.71 billion, providing ample resources for R&D and acquisitions.
- Solid balance sheet with low debt: Debt-to-equity is only 0.21, and the current ratio is 2.9, indicating strong liquidity. This financial flexibility supports continued investment in pipeline and strategic deals without straining the balance sheet.
Bearish
- Decelerating revenue growth: Q1 2026 revenue growth slowed to 7.8% YoY, down from 16.5% in Q1 2025. As the CF market matures, growth is increasingly dependent on new product launches, which carry execution risks.
- High valuation with limited upside: The trailing PE of 29.3x and forward PE of 24.6x are premium to the market, yet the average analyst target of $563.12 implies only 3.96% upside. This suggests the stock is fairly valued, leaving little room for error.
- Pipeline execution risks: New products like Casgevy and Journavx are in early commercial stages, with uncertain adoption. The kidney drug's approval is pending, and any clinical or regulatory setback could significantly impact the growth narrative.
- Acquisition integration and premium: Vertex paid a 102% premium for Crinetics, a $10 billion deal. Integration risks and the high price could dilute returns if the acquired pipeline underperforms, as seen in many pharma M&A cases.
VRTX Technical Analysis
Vertex's stock is in a strong uptrend, with a 1-year price change of +38.17% and currently trading at $541.69, which is 97.5% of its 52-week range (low of $374.17, high of $555.69). This positioning near the highs indicates robust momentum and investor confidence, though it also suggests the stock may be vulnerable to profit-taking or a short-term pullback. The stock has outperformed the S&P 500 significantly over the past year (relative strength of +19.61%), underscoring its relative strength in the market.
Beta
0.32
0.32x market volatility
Max Drawdown
-22.4%
Largest decline past year
52-Week Range
$374-$560
Price range past year
Annual Return
+37.6%
Cumulative gain past year
| Period | VRTX Return | S&P 500 |
|---|---|---|
| 1m | +12.6% | +0.1% |
| 3m | +22.2% | +4.4% |
| 6m | +19.6% | +14.6% |
| 1y | +37.6% | +18.6% |
| ytd | +20.8% | +12.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
VRTX Fundamental Analysis
Vertex's revenue growth is solid but decelerating, with Q1 2026 revenue of $2.99 billion, up 7.8% year-over-year, compared to a 16.5% growth rate in Q1 2025. The company's CF franchise remains the primary driver, with Trikafta/Kaftrio contributing $2.35 billion in Q1 2026, while new products like Alyftrek ($424 million) and other manufactured products ($136 million) are adding incremental growth. The deceleration is expected as the CF market matures, but the pipeline (Casgevy, Journavx, kidney drug) is poised to re-accelerate growth in the coming years.
Quarterly Revenue
$3.0B
2026-03
Revenue YoY Growth
+7.8%
YoY Comparison
Gross Margin
86.9%
Latest Quarter
Free Cash Flow
$3.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is VRTX Overvalued?
Given Vertex's positive net income, the PE ratio is the primary valuation metric. The trailing PE is 29.32x, while the forward PE is 24.63x, indicating that the market expects earnings growth of approximately 19% over the next year. This forward discount suggests optimism about future profitability, driven by new product launches and pipeline progress. The PEG ratio is negative (-0.03) due to a negative earnings growth rate in the trailing twelve months (impacted by a one-time charge in Q2 2024), which is not meaningful for forward-looking analysis.
PE
29.3x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 14x~29x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
23.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks include a high reliance on the CF franchise, which accounts for the majority of revenue, and decelerating growth (7.8% YoY in Q1 2026). The company's high gross margin (85%) and operating margin (39.4%) are strong, but the $10 billion Crinetics acquisition adds integration risk and a 102% premium, which could pressure returns if synergies fail to materialize. Additionally, the negative PEG ratio and earnings volatility from one-time charges (e.g., Q2 2024) highlight potential earnings unpredictability.
FAQ
The key risks are: 1) Pipeline execution risk, as the kidney drug and Casgevy are critical for growth; 2) Integration risk from the $10 billion Crinetics acquisition, which was at a 102% premium; 3) Competitive risk in pain management and CF, though a rival's failure has reduced CF competition; 4) Valuation risk, as the stock trades at a premium and any disappointment could lead to a de-rating. The most severe risk is a pipeline failure, which could drive the stock down to the 52-week low of $374.17.
The 12-month forecast is based on three scenarios: Bull case (30% probability) targets $600-$672, driven by successful kidney drug approval and strong Casgevy uptake; Base case (50% probability) targets $540-$580, with steady but modest growth; Bear case (20% probability) targets $400-$450, if pipeline setbacks occur. The most likely scenario is the base case, with the stock trading near the analyst average target of $563.12, assuming continued CF growth and gradual pipeline contributions.
Vertex's trailing PE of 29.3x and forward PE of 24.6x are premium to the broader market, but they are justified by its high margins and growth potential. The PEG ratio is negative due to a one-time charge, making it unreliable. Compared to its own history, the stock is trading near the high end of its valuation range, but the market is pricing in successful pipeline execution. Overall, VRTX is fairly valued, with the average analyst target implying only 3.96% upside, suggesting the market has already priced in much of the good news.
Vertex is a good buy for investors with a long-term horizon who believe in its pipeline diversification. The stock offers a reasonable risk/reward with a consensus 'Buy' rating and an average analyst target of $563.12, implying a modest 3.96% upside. However, the downside risk is significant if pipeline setbacks occur, with the 52-week low at $374.17 representing a -30.9% decline. For those seeking growth with a defensive moat, VRTX is a solid addition, but it may not be a bargain at current levels.
Vertex is better suited for long-term investment due to its pipeline development cycle and the potential for significant value creation over several years. The stock has a low beta of 0.305, indicating lower volatility than the market, and no dividend, so investors rely on capital appreciation. With earnings visibility from the CF franchise and upcoming catalysts, a minimum holding period of 3-5 years is recommended to capture the full value of the pipeline. Short-term trading is possible given the stock's momentum, but it carries higher risk due to binary events like FDA decisions.